Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;63(2):332-340.
doi: 10.1007/s12020-018-1770-6. Epub 2018 Sep 29.

Prevalence and reproductive manifestations of macroprolactinemia

Affiliations

Prevalence and reproductive manifestations of macroprolactinemia

Amanpreet Kaur Kalsi et al. Endocrine. 2019 Feb.

Abstract

Purpose: Macroprolactinemia is characterized by predominance of macroprolactin molecules in circulation and generally has extra-pituitary origin. Macroprolactin is viewed as biologically inactive, therefore asymptomatic, and thus may not require any treatment or prolonged follow-up. In addition, data on prevalence of macroprolactinemia and its clinical manifestation are also rare. Therefore, the present study was aimed to find out prevalence of macroprolactinemia and its association, if any, with reproductive manifestations.

Material and methods: Macroprolactin was measured in 102 hyperprolactinemia cases (>100 ng/ml prolactin level), 135 physiological hyperprolactinemia cases (50 pregnant and 85 lactating females; >100 ng/ml prolactin level) and 24 controls. Poly ethylene glycol (PEG) precipitation method was carried out to screen macroprolactin. Prolactin recovery of <25% was considered overt macroprolactinemia. Detailed clinical data was recorded which included complete medical history, physical examination and hormone measurements besides CT/MRI for pituitary abnormalities.

Results: Prevalence of macroprolactinemia was 21.57% (22/102) in hyperprolactinemia (prolactin >100 ng/ml). There was no case of macroprolactinemia in physiological hyperprolactinemia, or healthy control females. Reproductive manifestations were present in 72.73% (16/22) macroprolactinemia cases, out of which macroprolactinemia was the sole cause of associated reproductive manifestations in 68.7% (11/16) cases. Reversal of reproductive dysfunction/s was observed in five cases with appropriate treatment for high macroprolactin.

Conclusion: Macroprolactinemia prevalence was found to be 21.5%, out of which 72.73% cases had associated reproductive dysfunctions.

Keywords: Hyperprolactinemia; Macroprolactin; Macroprolactinemia; Polyethylene Glycol Precipitation; Prolactin.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Endocrine. 2003 Dec;22(3):267-73 - PubMed
    1. Clin Chim Acta. 2010 Feb;411(3-4):155-60 - PubMed
    1. J Clin Endocrinol Metab. 1985 Aug;61(2):258-64 - PubMed
    1. Clin Chem. 2003 Sep;49(9):1504-9 - PubMed
    1. Clin Chem Lab Med. 2016 Apr;54(4):519-22 - PubMed

MeSH terms

LinkOut - more resources